2022
DOI: 10.1182/blood-2022-166107
|View full text |Cite
|
Sign up to set email alerts
|

CAR.CD123-NK Cells Have an Equally Effective but Safer Off-Tumor/on-Target Profile As Compared to CARCD123-T Cells for the Treatment of Acute Myeloid Leukaemia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…They infused human hematopoietic cells from UCB to immunodeficient mice that were treated with either CAR-T, CAR-NK, or unmodified T or NK cells 10 weeks after transplantation. The results reflected that all mice that received CAR-T cells infusion developed acute toxicity and died 5 days after treatment, while OS rate of other mice was 100 % at day 15 [ 86 ]. Significantly, high expression of inhibitory receptors on the surface of NK cells will also limit the clinical effects of therapy [ 87 ].…”
Section: Car-nk Cell Therapy For Cancermentioning
confidence: 99%
“…They infused human hematopoietic cells from UCB to immunodeficient mice that were treated with either CAR-T, CAR-NK, or unmodified T or NK cells 10 weeks after transplantation. The results reflected that all mice that received CAR-T cells infusion developed acute toxicity and died 5 days after treatment, while OS rate of other mice was 100 % at day 15 [ 86 ]. Significantly, high expression of inhibitory receptors on the surface of NK cells will also limit the clinical effects of therapy [ 87 ].…”
Section: Car-nk Cell Therapy For Cancermentioning
confidence: 99%